T. Rowe Price Investment Management
HLVX

T. Rowe Price Investment Management’s HilleVax HLVX Stock Holding History

T. Rowe Price Investment Management’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,481,222
Closed -$50.3M – 635
2024
Q2 		$50.3M Buy
3,481,222
+419,518
+14% +$5.76M 0.03% 386
2024
Q1 		$50.9M Buy
3,061,704
+1,607,914
+111% +$25.7M 0.03% 392
2023
Q4 		$23.3M Buy
1,453,790
+21,822
+2% +$290K 0.02% 471
2023
Q3 		$19.3M Buy
1,431,968
+7,033
+0.5% +$99K 0.01% 478
2023
Q2 		$24.5M Buy
1,424,935
+213,443
+18% +$3.31M 0.02% 462
2023
Q1 		$20M Buy
1,211,492
+170
+0% +$2.72K 0.01% 473
2022
Q4 		$20.3M Buy
1,211,322
+111,322
+10% +$2.01M 0.02% 458
2022
Q3 		$18.8M Buy
+1,100,000
New +$16M 0.02% 456

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

T. Rowe Price Investment Management's HLVX Position: Q3 2024 in Review

T. Rowe Price Investment Management sold out of HilleVax (HLVX) in Q3 2024, closing a stake of 3,481,222 shares — an estimated $50.3M sold.

T. Rowe Price Investment Management first reported a position in HLVX in Q3 2022 and held it in 8 quarters. The position peaked at $50.9M in Q1 2024. 79 funds tracked by Wall St. Rank hold HLVX as of Q3 2024.

  • T. Rowe Price Investment Management reported no remaining HilleVax position as of Q3 2024 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 3,481,222 HilleVax shares in Q3 2024, an estimated $50.3M.
  • T. Rowe Price Investment Management first reported a position in HilleVax in Q3 2022 and held it in 8 quarters.
  • T. Rowe Price Investment Management's HilleVax position peaked at $50.9M in Q1 2024.
  • 79 funds tracked by Wall St. Rank held HilleVax as of Q3 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.